1113 related articles for article (PubMed ID: 17494926)
1. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
[TBL] [Abstract][Full Text] [Related]
2. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
3. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
[TBL] [Abstract][Full Text] [Related]
4. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
Villa LL
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and incidence of HPV genital infection in women.
Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
FUTURE II Study Group
N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
[TBL] [Abstract][Full Text] [Related]
8. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
Yancey AM; Pitlick JM; Forinash AB
Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
[TBL] [Abstract][Full Text] [Related]
9. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
10. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
13. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
14. A human papillomavirus vaccine.
Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):65-6. PubMed ID: 16977280
[TBL] [Abstract][Full Text] [Related]
15. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
16. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus infections and vulvar disease development.
Garland SM; Insinga RP; Sings HL; Haupt RM; Joura EA
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1777-84. PubMed ID: 19505910
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
Broomall EM; Reynolds SM; Jacobson RM
Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
20. HPV vaccine and its recommendations, 2007.
Zimmerman RK
J Fam Pract; 2007 Feb; 56(2 Suppl Vaccines):S1-5, C1. PubMed ID: 17270106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
